Skip to main content
  1. Right Decisions
  2. Scottish Palliative Care Guidelines
  3. Back
  4. Medicines information
  5. Fentanyl nasal spray (PecFent)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Fentanyl nasal spray (PecFent)

Red – For medicines normally initiated and used under specialist guidance

Introduction

Description: Contains fentanyl, a potent opioid analgesic with a rapid onset of action.

Do not confuse with Alfentanil

Third line opioid: only for use with specialist advice

Preparations

  • PecFent contains fentanyl in a gel-based spray, administered intranasally, available as 100 microgram or 400 microgram per dose products containing 8 doses per bottle or
    32 dose pack available (4 x 8 doses per bottle).
  • Most NHS boards have only approved one or two rapid acting fentanyl products for use in their area. Refer to your local Formulary (Abstral and Effentora medicine information sheets).
  • Rapid acting fentanyl products have different absorption and elimination characteristics and are not interchangeable. Start with the lowest dose and titrate very carefully if the patient is changed to a different product.
  • The brand name should always be included in the prescription.

 

Indications

  • Rapid acting fentanyl preparations are SMC approved for restricted use in NHSScotland; for the management of opioid responsive, breakthrough pain in adults requiring regular opioid therapy for chronic cancer pain.
  • Use is restricted to patients where other oral opioids (for example immediate-release morphine or immediate-release oxycodone) are unsuitable, ineffective or not tolerated.
  • Patients must have been on a stable dose of a regular opioid for at least 7 days equivalent to at least 60mg of oral morphine or 30mg of oral oxycodone in 24 hours or a 25 micrograms/hour fentanyl patch before rapid acting fentanyl is used.
  • Opioids with a rapid onset of action can be effective in breakthrough pain where background cancer pain is well controlled but the patient has:
    • pain related to a particular event (for example movement, dressing changes)
    • pain that occurs spontaneously, is sudden in onset, is moderate to severe, but may not last long.

 

Cautions

  • Hepatic metabolism to an inactive metabolite is slower when higher doses of fentanyl are used.
  • Rapid acting fentanyl products can have a variable and unpredictable half life which in some products can be up to 22 hours.
  • Liver impairment: lower doses and slower titration are needed in severe liver disease.
  • Renal impairment: no initial dose reduction. May accumulate gradually over time in patients with Grade 4-5 chronic kidney disease. Fentanyl is not removed by dialysis.
  • Monitor patients with liver or renal impairment and reduce the dose if side effects develop.
  • Avoid in patients with severe chronic obstructive pulmonary disease or respiratory depression.

 

Drug Interactions

  • Hepatic metabolism is reduced by grapefruit juice and a number of medications
    (for example fluconazole, QTclarithromycin, QTerythromycin) – refer to British National
    Formulary (BNF).
  • Alcohol and central nervous system depressants increase side effects.
  • Nasal decongestants (for example oxymetazoline) decrease absorption.

Manufacturers warn of a risk of serotonin toxicity when fentanyl is used in combination with other serotoninergic drugs.

 

Side effects

  • Similar to other opioids: nausea, dizziness, sedation, delirium.
  • Rapid acting fentanyl preparations can accumulate if repeated doses are given.
  • Monitor the patient closely for opioid side effects; review the dose and dosing interval.
  • Titrated naloxone is only indicated in life-threatening, opioid induced respiratory depression (refer to Naloxone guideline).

 

Dose and administration

  • Rapid acting fentanyl preparations must be individually titrated to an effective dose; patients should be monitored closely during the initial dose titration period.
  • The effective dose of rapid acting fentanyl cannot be predicted from the dose of regular opioid being used to manage background pain.
  • The licensed titration regimen may be too complex for some care settings and too rapid for some patients. In specialist palliative care there is little consensus on the most appropriate way to titrate the rapid acting fentanyl preparations – refer to local specialist advice. The regimen below is used by some specialists but is unlicensed (patients under specialist palliative care may have the dose escalated more quickly):
  • Start with the lowest dose of the fentanyl nasal spray (PecFent 100 micrograms):
    • one dose of PecFent can be given to treat an episode of pain or 5 to 10 minutes before an event anticipated to cause pain
    • if the patient is still in pain after taking one dose of PecFent as above, a dose of their usual immediate-release oral opioid is given
    • wait for 4 hours before treating another episode of breakthrough pain with PecFent
    • the dose of PecFent can be increased if it is effective and well tolerated, usually after 24 to 48 hours.
  • Patients whose initial dose is 100 micrograms and who require a higher dose due to lack of effect can be prescribed two 100 microgram sprays (one in each nostril) for their next breakthrough pain episode.
  • If this is unsuccessful, prescribe the higher concentration formulation
    (400 micrograms/spray) and give one 400 microgram spray for the next episode of pain.
  • If this dose is unsuccessful give two 400 microgram sprays (one spray in each nostril – maximum dose is 800 micrograms). Palliative care specialists may recommend an individualised titration regimen.
    • Continue to monitor the patient carefully.
    • A maximum of 4 episodes of breakthrough pain in 24 hours should be treated with fentanyl nasal spray.
  • Make sure background pain is well controlled with regular opioids and other analgesics.
  • If pain remains poorly controlled, review the patient, reassess the background analgesia, and consider other approaches to pain management.

Rapid acting fentanyl should be discontinued if it is ineffective or no longer needed.

 

Practice points

  • Seek advice from a specialist about use of rapid acting fentanyl products.
  • Fentanyl is 100 to 150 times more potent than oral morphine; titrate and monitor carefully.
  • Even the lowest strength preparations can accumulate and cause opioid toxicity.
  • Different rapid acting fentanyl products should not be used at the same time.
  • The GP, community nurse and community pharmacist should be informed.
  • The unscheduled care service should be informed that the patient is receiving a third line opioid under specialist supervision.
  • Fentanyl nasal spray (PecFent®) can be prescribed by the patient’s GP in liaison with local palliative care specialists.
  • If the product has not been used for 5 days, re-prime by spraying once. Discard bottle
    60 days after first opening.
  • Patients may not always feel the spray so should be encouraged to listen for the audible click.
  • The patient should have information about who to contact if there are any queries or problems relating to use of PecFent® in the community.

 

Resources

Summary of product characteristics for PecFent from the electronic medicines compendium:

 

References

Davies A. The management of cancer related breakthrough pain: recommendations of a task group of the Association for Palliative Medicine. European Journal of Pain; 2009, 13 (4): 331-338.